Skip to main content

Table 4 Manganese superoxide dismutase -102 genotype: overall and recurrence-free survivals with adjuvant chemotherapy

From: Association between manganese superoxide dismutase promoter gene polymorphism and breast cancer survival

Genotype

Cases

Deaths

Hazard ratio minimally adjusteda (95% confidence interval)

Hazard ratio fully adjustedb (95% confidence interval)

Overall survival

230

75

P for trend = 0.46

P for trend = 0.42

   CC

140

49

1 (reference)

1 (reference)

   CT

73

21

0.83 (0.49–1.38)

0.67 (0.38–1.17)

   TT

17

5

0.81 (0.32–2.04)

1.07 (0.42–2.74)

   CC

140

49

1 (reference)

1 (reference)

   CT + TT

90

26

0.82 (0.51–1.33)

0.73 (0.44–1.22)

Recurrence-free survival

220

85

P for trend = 0.16

P for trend = 0.12

   CC

136

57

1 (reference)

1 (reference)

   CT

68

24

0.79 (0.49–1.28)

0.64 (0.38–1.07)

   TT

16

4

0.55 (0.20–1.52)

0.73 (0.26–2.049)

   CC

136

57

1 (reference)

1 (reference)

   CT + TT

84

28

0.75 (0.47–1.18)

0.65 (0.40–1.05)

  1. CC, homozygous for the wild-type manganese superoxide dismutase gene; CT, heterozygous for the variant genotype; TT, homozygous for the variant genotype. aMinimally adjusted model: age. bFully adjusted model: age, stage with node status at diagnosis, race, estrogen receptor status, and progesterone receptor status.